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1. Abstract 24 
In this study, a rapid method for the detection of Central and West Africa clades of 25 
Monkeypox virus (MPXV) using recombinase polymerase amplification (RPA) assay 26 
targeting the G2R gene was developed. MPXV, an Orthopoxvirus, is a zoonotic dsDNA 27 
virus, which is listed as a biothreat agent. RPA was operated at a single constant 28 
temperature of 42°C and produced results within 3 to 10 minutes. The MPXV-RPA-assay 29 
was highly sensitive with a limit of detection of 16 DNA molecules/μl. The clinical 30 
performance of the MPXV-RPA-assay was tested using 47 sera and whole blood samples 31 
from humans collected during the recent MPXV outbreak in Nigeria as well as 48 plasma 32 
samples from monkeys some of which were experimentally infected with MPXV. The 33 
specificity of the MPXV-RPA-assay was 100% (50/50), while the sensitivity was 95% 34 
(43/45). This new MPXV-RPA-assay is fast and can be easily utilised at low resource 35 
settings using a solar powered mobile suitcase laboratory. 36 
 37 
 38 
 39 
 40 
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Highlights: 44 
1. Monkeypox virus infections can be detected in ten minutes 45 
2. The assay based on an isothermal amplification technology named recombinase 46 
polymerase amplification 47 
3. The whole procedure can be operated by a mobile suitcase laboratory 48 
 49 
 50 
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2. Introduction 54 
Monkeypox virus (MPXV) belongs to the genus Orthopoxvirus (OPXV, subfamily 55 
Chordopoxvirinae, family Poxviridae), which is an enveloped double stranded DNA virus 56 
[1]. It is subdivided into two clades: the West African and the Congo Basin clades. The 57 
latter is more pathogenic [2] and the clinical signs of MPXV infections are similar to that of 58 
smallpox but in a milder form and with lower mortality (1 to 10%). The majority of deaths 59 
occurs at a young age due to the lack of immunization [3]. Rodents (Squirrels and 60 
Gambian rats) are the primary hosts [4,5], which can transmit the virus to monkeys and 61 
humans through direct contact with blood and bodily fluids [6]. The handling and 62 
consumption of infected monkeys and squirrels were documented as major infection 63 
sources in Africa [7]. Furthermore, human-to-human transmission can occur through 64 
exposure to fomites and air droplets [8]. A specific vaccine for use in humans is not 65 
available, but cross protection in humans vaccinated against smallpox has been 66 
documented [9]. This protection however, has been waning because when smallpox was 67 
declared eradicated in 1980, nationwide vaccination against smallpox has stopped [10]. 68 
The antiviral tecovirimat for treatment of accidental smallpox infections has been shown to 69 
reduce symptoms and to improve survival of MPXV infected macaques if applied up to 5 70 
days post infection [11]. 71 
Human MPXV infections are endemic in West and Central Africa [12]. The first MPXV 72 
outbreak outside Africa was reported in 2003 in the USA after the shipment of animals 73 
from Ghana [13]. The latest outbreak was in Nigeria with 113 laboratory confirmed cases 74 
and seven deaths from September 2017 until August 2018 [14]. Two recent zoonotic 75 
MPVX infections imported in the UK highlight ongoing MPXV activity in Nigeria [15]. 76 
4 
Several diagnostic methods for the detection of MPXV are established with real-time PCR 77 
as the gold standard because of its high sensitivity and specificity [16]. To use this 78 
diagnostic tool, a highly equipped laboratory and specialized technicians are needed, 79 
which are not available in areas where MPXV infections occur. Therefore, an easy to 80 
handle simple molecular diagnostic method would improve the detection and surveillance 81 
of MPXV. Isothermal amplification methods have been proven to be an alternative to real-82 
time PCR. Recombinase polymerase amplification (RPA) is one of these methods, in 83 
which an enzymatic based DNA amplification can be achieved at a temperature range of 84 
37 to 42°C within 15 minutes [17]. The amplification is initiated by a primer-recombinase-85 
complex. This complex invades the DNA double strand at the homologues sequences of 86 
the primer, where single-strand-binding proteins stabilize the reaction. Then, a strand-87 
displacing polymerase DNA conducts the extension step. For real-time detection, a 88 
fluorophore/quencher-probe is used. Since RPA reagents are freeze-dried, the RPA kit 89 
can be stored at room temperature for several months. This allows the use of the RPA 90 
assay at point of need making them even more versatile through a mobile suitcase 91 
laboratory [18].  92 
In this study, we have developed a rapid detection method specific for both clades of 93 
MPXV using a recombinase polymerase amplification (RPA) assay targeting the tumor 94 
necrosis factor (TNF) binding protein gene, which is present in duplicate as ORF G2L and 95 
G2R in the inverted terminal repeats of the MPXV genome. 96 
 97 
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3. Materials and Methods 106 
3.1. Molecular MPXV DNA Standard and RPA Oligonucleotide  107 
For assay validation, a molecular DNA standard based on 300 bp of the TNF binding 108 
protein gene (ORF: G2R, Accession number: DQ011153, nucleotides: 195915 - 196964), 109 
was synthesized by GeneArt (Regensburg, Germany). Three forward primers (FP), three 110 
reverse primers (RP) and one exo-probe were designed (Figure S1). All oligos were 111 
synthesized by TIB MOLBIOL GmbH (Berlin, Germany). 112 
 113 
3.3. RPA Assay Conditions 114 
The TwistAmp exo kit (TwistDx Ltd, Cambridge, UK) was used. Per reaction, 29.5 µl 115 
rehydration buffer, 10.7 µl H2O, 2.1 µl of each primer (10 µM) and 0.6 µl of 10 µM exo-116 
probe were added into the lid of the reaction tube containing the freeze-dried pellet. After 117 
adding 2.5 µl of 280 mM magnesium acetate and 1 µl template, the reaction mixture was 118 
centrifuged, mixed, centrifuged and placed immediately into the tube scanner ESEQuant 119 
(QIAGEN Lake Constance GmbH, Stockach, Germany). The reaction was incubated at 120 
42°C for 15 minutes. To increase the sensitivity, a mixing and centrifugation step was 121 
performed after 230 seconds of starting the measurement. A positive result was measured 122 
by the FAM channel of the ESEQuant tube scanner and analysed with the Tubescanner 123 
studio software (version 2.07.06, QIAGEN Lake Constance GmbH, Stockach, Germany).  124 
 125 
3.4. MPXV RPA Assay Analytical Sensitivity  126 
6 
In total, nine primer combinations were tested with the MPXV DNA standard with 127 
concentration of 105 DNA molecules/µl. The best combination, which produced the earliest 128 
and highest fluorescence signal, was selected for further assay validation. The ability of 129 
the selected primer combination to amplify 104 to 1 DNA molecules/µl of the MPXV 130 
standard DNA was checked in order to test the analytical sensitivity and to determine the 131 
limit of detection.  132 
 133 
3.5. MPXV RPA assay cross reactivity  134 
The specificity of the MPXV-RPA-assay was tested with DNA of viruses of the two MPXV 135 
clades, six other pox viruses and other pathogens of clinical importance, see table 1.  136 
 137 
Table 1: Reactivity of the MPXV_RPA assay to the genome of poxviruses and other 138 
pathogens. MPXV_RPA assay detected both clades of MPXV, but not other poxviruses 139 
and pathogens. 140 
Pathogen Clade/ Source 
Concentration 
[ng/µl] 
RPA 
Real-time 
PCR 
Monkeypox   Central Africa  + + 
Monkeypox   West Africa  + + 
Vaccinia  Elstree 7.6 - - 
Cowpox  2 3.6 - - 
Camelpox - 18 - - 
Sheeppox  Russia 4.6 - - 
Goatpox  India 3.1 - - 
Orf  Burghessler 3 - - 
Calpox virus - 6.1 - - 
Herpes-simplex-Virus 1  Quality Control for 
Molecular 
Diagnostics 
(QCMD) 
1.7 - - 
Herpes-simplex-Virus 2 3.6 - - 
Varicella-zoster Virus 3.1 - - 
Staphylococcus aureus DSMZ ID: 1104 4.2 - - 
Clostridium perfringes DSMZ ID: 756 40.2 - - 
7 
Enterococcus faecialis DSMZ ID: 20478 35.2 - - 
Plasmodium falciparum 
University of 
Ibadan, Nigeria 
2.8 - - 
Rickettsia rickettsia BNITM Hamburg, 
Germany 
4.7 - - 
Rickettsia africae 4.3 - - 
3.6. Clinical samples 141 
The MPXV-RPA-assay performance was validated with plasma samples of infected (n=25) 142 
and uninfected (n=23) monkeys. The animals were looked after by experienced personnel 143 
from the German Primate Center and kept according to the German Animal Welfare Act, 144 
which is in compliance with the European Union Guidelines on the use of non-human 145 
primates for biological research and the Weatherall report. Sampling from MPXV-infected 146 
monkeys was approved by the Lower Saxony State Office of Consumer Production and 147 
Food Safety with the project license 33.9.42502-04/019/07, that from uninfected animals 148 
with the project license 33.9.42502-04-15/1769. In addition, 20 positive (4 whole blood, 16 149 
serum) and 27 negative (8 whole blood, 19 serum) human samples from the recent MPXV 150 
outbreak in Nigeria (November 2017) were tested with the RPA-MPXV-assay. The 151 
samples were collected for diagnostics purposes and handled anonymously. The DNA 152 
from these samples was isolated using the QIAamp DNA Mini Kit (QIAGEN, Hilden, 153 
Germany) following the manufacturer instructions. 154 
  155 
 156 
3.7 Real-time PCR  157 
For comparison, the molecular DNA standards as well as clinical samples were tested with 158 
a reference MPXV real-time PCR assay targeting the same gene region of the developed 159 
RPA assay [19]. The G2R-G real-time PCR assay detects both MPXV clades and the real-160 
time PCR reaction was performed as described previously [20] using the LightCycler DNA-161 
Master HybProbe kit and the LightCycler 480 (Roche Mannheim, Germany). 162 
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3.8. Statistical Analysis 166 
The limit of detection of the MPXV-RPA-assay was calculated by performing a probit 167 
regression analysis on the data set of eight RPA assay using STATISTICA software 168 
(StatSoft, Hamburg, Germany) in order to determine the number of DNA molecules/µl, 169 
which were detected in 95% of the cases. Furthermore, the detection time was calculated 170 
by performing a semi-logarithmic regression on the same data set with GraphPad PRISM 171 
7 software (GraphPad Software Inc., San Diego, California). 172 
 173 
4. Result 174 
4.1 Selection of RPA Primers and Probe 175 
In order to select sensitive RPA oligonucleotides, all possible primer combinations were 176 
tested using a MPXV DNA molecular standard at a concentration of 105 DNA molecules/µl. 177 
As a result, the primer combination FP3 + RP3 (Table 2) produced the best amplification 178 
curves (Figure S1) and was selected for further assay validation.  179 
 180 
Table 2. RPA primers and exo-probe combination, yielding the earliest and highest 181 
signal in the MPXV RPA assay. QTF are sites of the quencher and fluorophore in the 182 
following order BHQ1-dt (Q), Tetrahydrofuran (T) and Fam-dT (F). 183 
Name Sequence (5´ to 3´) 
MPXV RPA P1 ACAGAAGCCGTAATCTATGTTGTCTATCGQTFCCTCCGGGAACTTA 
9 
MPXV RPA FP3 AATAAACGGAAGAGATATAGCACCACATGCAC 
MPXV RPA RP3 GTGAGATGTAAAGGTATCCGAACCACACG 
 184 
4.2 Analytical Sensitivity and Specificity  185 
To determine the analytical sensitivity, the performance of the best primer combination 186 
FP3 and RP3 was evaluated with a tenfold dilution range of the MPXV DNA standard (104 187 
to 1 DNA molecules/µl, Figure 1) in eight replicates. The MPXV-RPA-assay detected the 188 
molecular MPXV DNA standard with the concentration from 104 to 102 molecules/µl in all 189 
eight RPA runs and the concentration of 101 molecules/µl in four runs, while no 190 
amplification was observed in the tube containing one molecule/µl. With this data set, a 191 
probit regression analysis was performed and revealed a detection limit of 16 DNA 192 
molecules/µl in 95% of the cases (Figure 2). Seven minutes is the maximum time needed 193 
to amplify as low as 10 DNA molecules by the MPXV RPA assay (Figure 3). FP3 and RP3 194 
primers were able to amplify the two clades of MPXV but did not detect high concentration 195 
DNA of related poxviruses or other pathogens (Table 1). 196 
 197 
Figure 1. Analytical sensitivity of the MPXV-RPA-assay tested with a tenfold dilution 198 
of the molecular DNA standard (104 – 100 DNA molecules/µl). The primer combination 199 
10 
FP3 + RP3 detected the concentration 104 – 101 DNA molecules/µl. After 230 seconds a 200 
mixing step was performed.  201 
 202 
Figure 2. Probit regression analysis of the dataset of the eight repetitions of the 203 
analytical sensitivity test of the MPXV-RPA-assay for the determination of the 204 
detection limit (A) and semi-logarithmic regression of the detection time (B). 205 
Performing the probit regression analysis on the dataset revealed a detection limit of 16 206 
DNA molecules/µl in 95% of the cases (A). Using Prism Software, a semi-logarithmic 207 
regression of the data from the eight runs on a dilution range of the molecular DNA 208 
standard (104-100 DNA molecules/reaction) were performed. The lowest concentration of 209 
101 DNA molecules/µl was detected after a maximum of seven minutes (B). 210 
 211 
 212 
11 
 213 
Figure 3. Screening of 45 blood, plasma or serum samples from MXPV infected 214 
macaques and humans by real-time PCR and RPA assays. Linear regression analysis 215 
of real-time RT-PCR cycle threshold values (Ct) and RPA threshold time in minutes (TT) 216 
were determined. No correlation was found between TT and Ct values since the RPA is 217 
much faster than the real-time PCR. Diagnostic sensitivity of real-time PCR assay was 218 
100%, while that of MPXV-RPA-assay was 95 %(43/45). 219 
 220 
4.3. Clinical Samples 221 
All collected samples were screened in parallel with both real-time PCR and the RPA 222 
assays. Employing the real-time PCR assay, all 45 samples tested positive, while by the 223 
RPA assay 43/45 were identified as positive. Fifty samples (23 monkey plasma and 27 224 
human serum and whole blood samples) were negative in both methods. With this data, 225 
the clinical specificity and sensitivity of the MPXV-RPA-assay could be calculated as 100 226 
and 95%, respectively.  227 
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5. Discussion 228 
Infection with MPXV occurs in West Africa and the Congo Basin [12]. The most affected 229 
regions suffer from limited resources, infrastructure and diagnostic capacities, beside 230 
insufficient accessibility to remote and conflict areas. Thus, identification of MPXV infected 231 
cases is difficult [21]. Therefore, a simple point of need diagnostic test is crucial in order to 232 
limit the spread of MPXV and control the outbreaks.  233 
Applying the MPXV-RPA-assay both the West Africa and the Congo Basin clade were 234 
detected within seven minutes with a detection limit of 16 DNA molecules/µl. The RPA 235 
oligonucleotides target the TNF receptor gene as no mismatch between both MPXV 236 
clades was identified and thus cover the currently known diversity of MPXV, while between 237 
13-31 mismatches were identified when this sequence was compared to those of other 238 
poxviruses (Figure S3). The number of mismatches between the targeted MPXV gene 239 
sequence and the sequences of closely related poxviruses was the key to a specific RPA 240 
assay. Two samples were negative in the RPA assay but weakly positive in real-time PCR 241 
(CT: 38.8 and 39.97). Eight samples with CT values around 38-39 and eight samples with 242 
CT values 35-37 were scored positive in the RPA. All these samples had low DNA levels 243 
and lack of positive scoring of two samples in the RPA lay within the probability of missing 244 
weak positives as shown by the probit anaylsis.   245 
Real-time PCR assays for MPXV detection need at least 90 minutes and highly 246 
sophisticated thermal cycler [19]. Although freeze-dried PCR reagents are slowly 247 
becoming available [22], they are as yet not in widespread use, whereas the RPA kits per 248 
se are freeze-dried and stable under different environmental conditions including 249 
temperatures above 30°C [23]. This is a huge advantage in areas where highly equipped 250 
laboratories are not available. When comparing the performance of the MPXV-RPA-assay 251 
with the real-time PCR assay on clinical samples with linear regression analysis, no 252 
correlation was found between TT and Ct values since the RPA is much faster than the 253 
13 
real-time PCR (Figure 3). One reason for this observation for several RPA assays [23-25] 254 
is that the RPA reaction is optimized for maximal enzymatic activity at one temperature 255 
leading to very dynamic non linear amplification [17], whereas the real-time PCR reaction 256 
depends on different temperature steps for denaturation, annealing and amplification 257 
yielding a close to exponential amplification [26].  258 
Another isothermal amplification assay based on loop-mediated isothermal amplification 259 
for the detection of MPXV is available [27]. This assay has a clinical sensitivity of 72%. 260 
However, our MPXV-RPA-assay proved to be more sensitive (95 % sensitivity). The LAMP 261 
MPXV assay requires 6 primers to amplify the MPXV DNA in around 60 minutes, while 262 
RPA uses two primers and one probe producing a result within 15 minutes.  263 
The MPXV-RPA-assay appears an appropriate assay for the point of need detection of 264 
active MPXV cases as RPA is fast, highly sensitive and specific as well as utilizing cold-265 
chain independent reagents.  266 
 267 
 268 
 269 
 270 
 271 
 272 
 273 
 274 
 275 
 276 
 277 
 278 
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Figure 1. Analytical sensitivity of the MPXV-RPA-assay tested with a tenfold dilution of the molecular DNA standard (104
– 100 DNA molecules/µl). The primer combination FP3 + RP3 detected the concentration 104 – 101 DNA molecules/µl. After 230
seconds a mixing step was performed.
Figure 2. Probit regression analysis of the dataset of the eight repetitions of the analytical sensitivity test of the MPXV-RPA-assay for the determination of the
detection limit (A) and semi-logarithmic regression of the detection time (B). Performing the probit regression analysis on the dataset revealed a detection limit of 16 DNA
molecules/µl in 95% of the cases (A). Using Prism Software, a semi-logarithmic regression of the data from the eight runs on a dilution range of the molecular DNA standard (104-
100 DNAmolecules/reaction) were performed. The lowest concentration of 101 DNAmolecules/µl was detected after a maximum of seven minutes (B).
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Figure 3. Screening of 45 blood, plasma or serum samples from MXPV infected macaques and
humans by real-time PCR and RPA assays. Linear regression analysis of real-time RT-PCR cycle
threshold values (Ct) and RPA threshold time in minutes (TT) were determined. No correlation was
found between TT and Ct values since the RPA is much faster than the real-time PCR. Diagnostic
sensitivity of real-time PCR assay was 100%, while that of MPXV-RPA-assay was 95 %(43/45).
Table 1: Reactivity of the MPXV_RPA assay to the genome of poxviruses and 
other pathogens. MPXV_RPA assay detected both clades of MPXV, but not other 
poxviruses and pathogens. 
Pathogen Clade/ Source 
Concentration 
[ng/µl] 
RPA 
Real-time 
PCR 
Monkeypox   Central Africa  + + 
Monkeypox   West Africa  + + 
Vaccinia  Elstree 7.6 - - 
Cowpox  2 3.6 - - 
Camelpox - 18 - - 
Sheeppox  Russia 4.6 - - 
Goatpox  India 3.1 - - 
Orf  Burghessler 3 - - 
Calpox virus - 6.1 - - 
Herpes-simplex-Virus 1  Quality Control for 
Molecular 
Diagnostics 
(QCMD) 
1.7 - - 
Herpes-simplex-Virus 2 3.6 - - 
Varicella-zoster Virus 3.1 - - 
Staphylococcus aureus DSMZ ID: 1104 4.2 - - 
Clostridium perfringes DSMZ ID: 756 40.2 - - 
Enterococcus faecialis DSMZ ID: 20478 35.2 - - 
Plasmodium falciparum 
University of 
Ibadan, Nigeria 
2.8 - - 
Rickettsia rickettsia BNITM Hamburg, 
Germany 
4.7 - - 
Rickettsia africae 4.3 - - 
 
Table 2. RPA primers and exo-probe combination, yielding the earliest and 
highest signal in the MPXV RPA assay. QTF are sites of the quencher and 
fluorophore in the following order BHQ1-dt (Q), Tetrahydrofuran (T) and Fam-
dT (F). 
Name Sequence (5´ to 3´) 
MPXV RPA P1 ACAGAAGCCGTAATCTATGTTGTCTATCGQTFCCTCCGGGAACTTA 
MPXV RPA FP3 AATAAACGGAAGAGATATAGCACCACATGCAC 
MPXV RPA RP3 GTGAGATGTAAAGGTATCCGAACCACACG 
 
Name Sequence (5´ to 3´) 
Amplicon 
MPXV Probe 
MPXV FP1 
MPXV FP2 
MPXV FP3 
MPXV RP1 rc 
MPXV RP2 rc 
MPXV RP3 rc 
AATAAACGGAAGAGATATAGCACCACATGCACCATCCAATGGAAAGTGTAAAGACAACGAATACAGAAGCCGTAATCTATGTTGTCTATCGTGTCCTCCGGGAACTTACGCTTCCAGATTATGTGATAGCAAGACTAATACACAATGTACACCGTGTGGTTCGGATACCTTTACATCTCACAAT 
--------------------------------------------------------------ACAGAAGCCGTAATCTATGTTGTCTATCGTNTCCTCCGGGAACTTA---------------------------------------------------------------------------- 
--------------------------------------------------AAGACAACGAATACAGAAGCCGTAATCTATG------------------------------------------------------------------------------------------------------- 
----------------ATAGCACCACATGCACCATCCAATGGAAAGT----------------------------------------------------------------------------------------------------------------------------------------- 
AATAAACGGAAGAGATATAGCACCACATGCAC-------------------------------------------------------------------------------------------------------------------------------------------------------- 
------------------------------------------------------------------------------------------------------------CGCTTCCAGATTATGTGATAGCAAGACTAAT--------------------------------------------- 
--------------------------------------------------------------------------------------------------------------------------------------CTAATACACAATGTACACCGTGTGGTTCGGAT------------------ 
--------------------------------------------------------------------------------------------------------------------------------------------------------CGTGTGGTTCGGATACCTTTACATCTCAC--- 
 
Figure S1. MPXV_RPA _assays amplicon as well as primer and probe sequences. MPXV-RPA-assay oligonucleotides were placed at 
nucleotides 195962-196146; Genbank accession number: DQ011153. Three forward and three reverse primers as well as one exo-probe were 
screened to select the combination with higher RPA analytical sensitivity. RC: reverse complementary sequence.  
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Figure S2. Testing of all possible primer combination of the MPXV-RPA-assay. All nine primer combination were tested with the
molecular DNA standard with a concentration of 105 DNA molecules/µl. A mixing step was conducted after 230 sec. The combination
FP3 + RP3 showed the earliest and highest fluorescence signal and was therefore chosen for further assay validation.
Virus 
        
 
MPX West African 
MPX Congo Basin 
Variola 
Vaccinia 
Camelpox 
Cowpox 
Sheeppox 
Goatpox 
 
AATAAACGGAAGAGATAT-AGCACCACAT----GCACCATCCAA--TGGAAAGTGT-AAAGACAA---CG-----AATACAGAAGCCGTAATCTATGTT-GTCTATCGTGTCCTCCG---GGAACTTACGCTTCCAGATTATG-TGATAGCAAGACTA------ATACACAATGTACA----CCGTGTGGTTCGGATACCTTTACATCTCAC 
..................-..........----...........--......A...-........---..-----........................-.................---.......................-..............------.............G----.............................. 
................GC-......GT..----A.....C....--..........-.......C-.-------.......A.C...A......G....-..T..............---.....A.................-..............------.C............----.............G..............G. 
..................-......G...----.........G.--..........-........---..-----......A.C...A....T.G...----------------...---.....A.................-C.............------.C...........G----.............G......C.......G. 
................G.-.A....GT..----...........--..........-........---..-----......A.C...A......G....-..T..............---.....A.................-C.............------.C...........G----.............G......C.......G. 
.......---..C.....-.A....G...----.A.........--C.........-........---..-----......A.C...A.C.........-..T..............---.....A.................-C.............ACACAA.C...........G----.......CG.....C........G....G. 
......T-.T...A.A..A...TA..A..ATCGAG..A..TA..AC.T.T..C.A.A...A.A..ATA..TTACA....A.AG.A.TT...AA......A..TG..--AT..AAAA.AGT......G.----AA.........A...A..T..T.A.T------T....G...TCG..GGTT..ACTATA.A......TGG..TA.AA...A 
......T-.T...A.A..A...CA..A..ATCGAG..A..TA..AC.T.T..C.A.-...A.A..ATA..TTACA....A.AG.A.TT...AA......A..TG..-..-...AAG.AGT......G.----AA.........A...A..T..T.A.T------T....GC..TC...GGTT..ACTATA.A......TGG..TA.AA...A 
Figure S3. Alignment of the MPXV-RPA-assays amplicon with the Congo Basin clade and other Chordopoxvirinae of interest. Using 
Geneious (Version: 11.1.2, Biomatters Limited, New Zealand) the target sequence of the G2R gene of the monkeypox West African virus 
(Genebank accession number: DQ011153, nucleotides: 195962 – 1969143) was compared with monkeypox Congo Basin virus (accession 
number: NC_003310, nt: 194120 – 194301), variola virus (accession number: NC_001611, nt: 182618 - 182749), vaccinia virus (accession 
number: NC_006998, nt: 189299 – 189472), camelpox virus (accession number: NC_003391, nt: 201497 – 201678) ,cowpox virus (accession 
number: NC_003663, nt: 219885 – 220071), sheeppox virus (accession number: NC_004002, nt: 112967 – 113171) and goatpox virus 
(accession number: NC_004003, nt: 112695 – 112892). Between 1 to 31 mismatches could be identified in the primers and probe sequences.  
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